Strategic Acquisition Signals Upcoming sales opportunities may arise from the 2021 acquisition by 858, suggesting potential channel shifts or new collaboration models. Engage with the acquirer or transitional leadership to explore pipeline integration, licensing, or co-development arrangements.

Epitranscriptomics Focus Gotham Therapeutics targets RNA-modifying proteins, a niche with rising interest in oncology, auto-immune, and neurodegenerative markets. Position offerings around high-value screening services, library access, and early lead optimization partnerships to accelerate epitranscriptomic programs.

Funding and Scale Signals With a disclosed funding of sixty million and revenue activity in the low single digits, the company is in a formative growth phase. Propose cost-efficient CRO collaborations, shared-risk chemistry campaigns, and scalable discovery platforms tailored for small molecule epitranscriptomic targets.

Partnership Network Historical collaborations with Mercachem and ZoBio indicate openness to alliance-based R&D. Target alliance, licensing, or services deals that leverage external libraries, compound libraries, and hit-to-lead capabilities to expand their pipeline efficiently.

Low Headcount, High Outsourcing Very small team implies a reliance on external partners for execution. Offer end-to-end discovery and development partnerships, protein target validation services, and out-sourced medicinal chemistry programs to de-risk internal bandwidth constraints.